ONC.TO : Summary for ONCOLYTICS BIO - Yahoo Finance

U.S. Markets closed

Oncolytics Biotech Inc. (ONC.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
0.940.00 (0.00%)
At close: 3:59PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.94
Open0.95
Bid0.94 x
Ask0.97 x
Day's Range0.94 - 0.98
52 Week Range0.19 - 1.13
Volume157,071
Avg. Volume324,152
Market Cap113.98M
Beta2.24
PE Ratio (TTM)-7.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research6 days ago

    ONCYF: REOLYSIN Clinical Development Plan

    On April 12, 2017, Oncolytics Biotech, Inc. (ONCYF) provided an outline of their path forward for developing REOLYSIN, their proprietary oncolytic virus used in the treatment of several cancers.  The company’s primary goal is to obtain regulatory approval for REOLYSIN in metastatic breast cancer based on the data presented at the American Academy of Cancer Research (AACR) Annual Meeting in early April.  Oncolytics will also develop REOLYSIN for other indications and in combination with other agents, such as checkpoint inhibitors and immunomodulatory imide drugs (IMiDs).

  • PR Newswire11 days ago

    Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan

    CALGARY, April 12, 2017 /PRNewswire/ - Oncolytics Biotech® Inc. (ONC.TO) (ONCYF) today announced its initial registration pathway and clinical development plan for REOLYSIN®, its proprietary immuno-oncology viral agent.  The Company's clinical development plan has two main objectives.  The primary objective is to obtain regulatory approval for REOLYSIN as quickly as possible and is based on the compelling metastatic breast cancer survival data recently presented at the American Academy of Cancer Research (AACR) Annual Meeting, in Washington, D.C.  The second objective is to expand REOLYSIN into commercially valuable new treatment areas that include immunotherapy and immunomodulatory (IMiD) agents in collaboration with pharmaceutical partners. At AACR the Canadian Cancer Trials Group (CCTG) presented positive overall survival (OS) data from an open-label, randomized, phase 2 study assessing the therapeutic combination of intravenously-administered REOLYSIN given in combination with the chemotherapy agent paclitaxel versus paclitaxel alone, in patients with advanced or metastatic breast cancer (IND 213).

  • CNW Group11 days ago

    Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan

    Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan